Discontinued — last reported Q4 '22

Business Segments · Restructuring (Note 20)

Consumer Health Business — Restructuring (Note 20)

Johnson & Johnson Consumer Health Business — Restructuring (Note 20) remained flat by 0.0% to $25.00M in Q4 2022 compared to the prior quarter.

Analysis

StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2022

How to read this metric

An increase reflects active efforts to improve efficiency, which may lead to short-term margin pressure but potential long-term cost savings. A decrease suggests that the segment has reached a period of operational stability.

Detailed definition

This metric tracks the costs associated with organizational changes, facility consolidations, and workforce adjustments...

Peer comparison

Similar to 'restructuring charges' or 'transformation costs' reported by diversified consumer goods and healthcare companies to highlight non-recurring operational improvements.

Metric ID: jnj_segment_consumer_health_business_restructuring_note_20

Historical Data

1 years
 FY'22
Value$100.00M

Frequently Asked Questions

What is Johnson & Johnson's consumer health business — restructuring (note 20)?
Johnson & Johnson (JNJ) reported consumer health business — restructuring (note 20) of $25.00M in Q4 2022.
What does consumer health business — restructuring (note 20) mean?
The expenses related to reorganizing or streamlining the operations of the consumer health business segment.